PregLem lines up €22.5M for pipeline work

Geneva-based PregLem ginned €22.5 million in its second venture round. San Francisco-based Sofinnova Partners led the round, with MVM Life Science Partners and NeoMed Management joining in. PregLem is developing a molecule that it in-licensed from France's HRA Pharma to treat pre-operative treatment of uterine myoma.

"In less than one year, PregLem has demonstrated its ability to in-license a portfolio of promising compounds to improve the treatment of a number of benign female reproductive health disorders," stated James Healy MD, PhD, General Partner at Sofinnova Ventures.

- check out the release for more info
- and here's the release on the most recent licensing deal

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.